Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.
Saved in:
| Title: | Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer. |
|---|---|
| Authors: | Moftakhar B; University of Rochester, Rochester, NY, USA. bmoftakhar@urmc.rochester.edu.; Wilmot Cancer Institute, University of Rochester Medical Center, 607 Elmwood Avenue, Box 704, Rochester, NY, 14642-0001, USA. bmoftakhar@urmc.rochester.edu., Lekkala M; University of Rochester, Rochester, NY, USA., Strawderman M; University of Rochester, Rochester, NY, USA., Smith TC; University of Rochester, Rochester, NY, USA., Meacham P; University of Rochester, Rochester, NY, USA., Fitzgerald B; University of Rochester, Rochester, NY, USA., Falkson CI; University of Rochester, Rochester, NY, USA., Dhakal A; University of Rochester, Rochester, NY, USA. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2020 Sep; Vol. 183 (2), pp. 411-418. Date of Electronic Publication: 2020 Jul 15. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-7217 |
|---|---|
| DOI: | 10.1007/s10549-020-05793-1 |
